Introduction: Ferric citrate (FC) is an FDA-approved iron-based phosphate binder for adults with dialysis-dependent chronic kidney disease. This study investigated the impact of FC as the primary phosphate-lowering therapy on utilization of erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron. Methods: In this randomized, open-label, active-controlled, multicenter study (NCT04922645), patients on dialysis and receiving ESAs were randomized to receive FC or remain on standard of care (SOC) phosphate-lowering therapy for up to 6 months. Primary endpoints were the difference in change from baseline to efficacy evaluation period (EEP) in mean monthly ESA and IV iron doses. Secondary endpoints included treatment differences in hemoglobin, phosphate, TSAT, and ferritin levels. Results: Two hundred nine patients were randomized to FC and had a day 1 dosing visit (n = 103) or SOC (n = 106). The two groups had similar baseline laboratory characteristics; however, atherosclerotic CV disease, peripheral vascular disease, and congestive heart failure were more common in the SOC group. The mean treatment difference in ESA monthly dose was −30.8 μg (FC vs. SOC; p = 0.02). An absolute though non-statistically significant change in mean monthly IV iron dose of −37.2 mg (p = 0.17) was observed with FC. Mean hemoglobin, TSAT, and ferritin all increased from baseline to the EEP with FC versus SOC. Serious adverse events occurred in 28% of patients receiving FC versus 37% in those receiving SOC. Conclusions: In patients receiving dialysis, treatment with FC as compared to remaining on SOC phosphate binders resulted in reductions in mean monthly ESA and IV iron dose.

1.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group
.
KDIGO clinical practice guideline for anemia in chronic kidney disease
.
Kidney Inter Suppl
.
2012
;
2
:
279
335
.
2.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group
.
KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD)
.
Kidney Int Suppl
.
2017
;
7
:
1
59
.
3.
Kovesdy
CP
,
Trivedi
BK
,
Kalantar-Zadeh
K
,
Anderson
JE
.
Association of anemia with outcomes in men with moderate and severe chronic kidney disease
.
Kidney Int
.
2006
;
69
(
3
):
560
4
.
4.
Fishbane
S
,
Pollack
S
,
Feldman
HI
,
Joffe
MM
.
Iron indices in chronic kidney disease in the national Health and nutritional examination survey 1988-2004
.
Clin J Am Soc Nephrol
.
2009
;
4
(
1
):
57
61
.
5.
Mircera FDA package insert, Updated 08/2015.
6.
Epogen FDA package insert, Updated 09/2017.
7.
Block
GA
,
Klassen
PS
,
Lazarus
JM
,
Ofsthun
N
,
Lowrie
EG
,
Chertow
GM
.
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis
.
J Am Soc Nephrol
.
2004
;
15
(
8
):
2208
18
.
8.
Auryxia (ferric citrate) [package insert]
.
Boston, MA
:
Keryx Biopharmaceuticals Inc.
;
2017
.
9.
Umanath
K
,
Jalal
DI
,
Greco
BA
,
Umeukeje
EM
,
Reisin
E
,
Manley
J
, et al
.
Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD
.
J Am Soc Nephrol
.
2015
;
26
(
10
):
2578
87
.
10.
Lewis
JB
,
Sika
M
,
Koury
MJ
,
Chuang
P
,
Schulman
G
,
Smith
MT
, et al
.
Ferric citrate controls phosphorus and delivers iron in patients on dialysis
.
J Am Soc Nephrol
.
2015
;
26
(
2
):
493
503
.
11.
Dwyer
JP
,
Sika
M
,
Schulman
G
,
Chang
IJ
,
Anger
M
,
Smith
M
, et al
.
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial
.
Am J Kidney Dis
.
2013
;
61
(
5
):
759
66
.
12.
Sinsakul
M
,
Sika
M
,
Koury
M
,
Shapiro
W
,
Greene
T
,
Dwyer
J
, et al
.
The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients
.
Nephron Clin Pract
.
2012
;
121
(
1–2
):
c25
9
.
13.
Cho
ME
,
Hansen
JL
,
Sauer
BC
,
Cheung
AK
,
Agarwal
A
,
Greene
T
.
Heart failure hospitalization risk associated with iron status in veterans with CKD
.
Clin J Am Soc Nephrol
.
2021
;
16
(
4
):
522
31
.
14.
Ponikowski
P
,
Kirwan
BA
,
Anker
SD
,
McDonagh
T
,
Dorobantu
M
,
Drozdz
J
, et al
.
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
.
Lancet
.
2020
;
396
(
10266
):
1895
904
.
15.
Macdougall
IC
,
Ponikowski
P
,
Stack
AG
,
Wheeler
DC
,
Anker
SD
,
Butler
J
, et al
.
Ferric carboxymaltose in iron-deficient patients with hospitalized heart failure and reduced kidney function
.
Clin J Am Soc Nephrol
.
2023
;
18
(
9
):
1124
34
.
16.
Moe
SM
,
Chertow
GM
,
Parfrey
PS
,
Kubo
Y
,
Block
GA
,
Correa-Rotter
R
, et al
.
Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial
.
Circulation
.
2015
;
132
(
1
):
27
39
.
17.
Macdougall
IC
,
White
C
,
Anker
SD
,
Bhandari
S
,
Farrington
K
,
Kalra
PA
, et al
.
Intravenous iron in patients undergoing maintenance hemodialysis
.
N Engl J Med
.
2019
;
380
(
5
):
447
58
.
You do not currently have access to this content.